Who was studied?
55 patients enrolled; 51 received treatment and formed the safety population; 49 were efficacy-evaluable. Participants had previously treated metastatic NSCLC without sensitizing EGFR/ALK alterations.
What does the publication report?
At median follow-up of 32.1 months, ORR was 36.7% (18/49), DCR 67.3% (33/49), and out-of-field response 30.6% (15/49). Median PFS was 5.9 months and median OS 18.4 months.
Safety findings
Any-grade treatment-related adverse events occurred in 44/51 patients (86.3%), and grade 3 events in 6/51 (11.8%); no grade 4–5 events were reported.
How should we interpret it?
Single-arm phase II evidence does not establish superiority over standard treatment. This is an independent related triplet trial, and overlaps its own 2021 safety run-in cohort; it is not a separate PRaG-series trial.
Read the original source
This independently written summary was checked against the original full publication. It is an educational summary, not a full-paper translation or clinical recommendation.
Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial · DOI: 10.1038/s41467-024-51807-7 · PMID: 39174542
Related publications from the same research program
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.